

Physical Activity and Reduced Risk of Cardiovascular Events Potential Mediating Mechanisms

Samia Mora, MD, MHS; Nancy Cook, ScD; Julie E. Buring, ScD;
Paul M Ridker, MD, MPH; I-Min Lee, MBBS, ScD

Background—Higher levels of physical activity are associated with fewer cardiovascular disease (CVD) events. Although the precise mechanisms underlying this inverse association are unclear, differences in several cardiovascular risk factors may mediate this effect.

Methods and Results—In a prospective study of 27 055 apparently healthy women, we measured baseline levels of hemoglobin A1c, traditional lipids (total, low-density lipoprotein, and high-density lipoprotein cholesterol), novel lipids [lipoprotein(a) and apolipoprotein A1 and B-100], creatinine, homocysteine, and inflammatory/hemostatic biomarkers (high-sensitivity C-reactive protein, fibrinogen, soluble intracellular adhesion molecule-1) and used women's self-reported physical activity, weight, height, hypertension, and diabetes. Mean follow-up was 10.9 ± 1.6 years, and 979 incident CVD events occurred. The risk of CVD decreased linearly with higher levels of activity (P for linear trend <0.001). Using the reference group of <200 kcal/wk of activity yielded age- and treatment-adjusted relative risk reductions associated with 200 to 599, 600 to 1499, and ≥ 1500 kcal/wk of 27%, 32%, and 41%, respectively. Differences in known risk factors explained a large proportion (59.0%) of the observed inverse association. When sets of risk factors were examined, inflammatory/hemostatic biomarkers made the largest contribution to lower risk (32.6%), followed by blood pressure (27.1%). Novel lipids contributed less to CVD risk reduction compared with traditional lipids (15.5% and 19.1%, respectively). Smaller contributions were attributed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine and creatinine had negligible effects ($<1\%$).

Conclusions—The inverse association between physical activity and CVD risk is mediated in substantial part by known risk factors, particularly inflammatory/hemostatic factors and blood pressure. (*Circulation*. 2007;116:2110-2118.)

Key Words: cardiovascular diseases ■ epidemiology ■ exercise ■ risk factors ■ women

Physical activity or fitness clearly reduces the risk of cardiovascular disease (CVD), with a magnitude of risk reduction comparable to that of not smoking.^{1,2} However, the precise mechanisms through which physical activity lowers CVD risk are not well understood. Even after traditional cardiovascular risk factors such as blood pressure, lipids, and diabetes are accounted for, the inverse relation between physical activity and CVD risk persists.³⁻⁷ Changes in individual risk factors with physical activity tend to be modest, on the order of 5% for blood lipids,^{8,9} 3 to 5 mm Hg for blood pressure,^{10,11} and 1% for hemoglobin A1c,¹² in contrast to the large reductions (30% to 50%) in CVD risk seen with physical activity.

Clinical Perspective p 2118

The relative contribution of these various risk factors, representing a number of physiological pathways, to the activity-related risk reduction in CVD is unknown. In addition, newly recognized CVD risk factors, in particular those relating to inflammation and hemostasis, also are modified favorably with physical activity.¹³⁻¹⁸ This likely represents an additional mechanistic pathway through which physical activity decreases CVD risk. Therefore, the aim of the present study was to quantify the contribution of traditional and novel risk factors to the activity-related reduction in CVD.

Received July 24, 2007; accepted September 14, 2007.

From the Donald W. Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention (S.M., N.C., J.E.B., P.M.R.), Leduq Center for Molecular and Genetic Epidemiology (S.M., P.M.R.), and Divisions of Preventive Medicine (S.M., N.C., J.E.B., P.M.R., I.-M.L.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women's Hospital, Harvard Medical School, and the Department of Epidemiology, Harvard School of Public Health (N.C., J.E.B., P.M.R., I.-M.L.), Boston, Mass.

Guest Editor for this article was Gregg C. Fonarow, MD.

Correspondence to Samia Mora, MD, MHS, Brigham and Women's Hospital, 900 Commonwealth Ave E, Third Floor, Boston, MA 02215. E-mail smora2@partners.org

© 2007 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.107.729939

Methods

Study Population

Study participants were drawn from the Women's Health Study (WHS), a recently completed trial of low-dose aspirin and vitamin E in the primary prevention of CVD in women.^{19–21} WHS participants were apparently healthy female healthcare professionals ≥ 45 years of age who were free of self-reported CVD and cancer at study entry (1992 to 1995). Women gave written informed consent and completed questionnaires at the time of enrollment on demographics, anthropometrics, medical history, medications, and lifestyle factors. They also were asked to provide a blood sample; 28 345 women did so. For this study, we excluded women with missing data on physical activity or body mass index ($n=544$) or missing information on the traditional or novel biomarkers of interest ($n=433$), leaving 27 055 women for analysis. The study was approved by the Institutional Review Board of the Brigham and Women's Hospital (Boston, Mass).

Assessment of Physical Activity and CVD Risk Factors

Physical activity was assessed at study entry with a questionnaire that has been shown to be valid and reliable.²² The correlation of activity reported on the questionnaires compared with activity diaries kept for 4 weeks over a year was 0.62.²² Participants were asked to estimate the average time per week over the past year spent on 8 groups of recreational activities and the number of flights of stairs climbed daily.²³ A metabolic equivalent task (MET) score was assigned to each activity on the basis of its energy cost. We estimated the energy expended on each of the above groups of activities and summed over all activities to estimate the total energy expended on physical activity (kcal/wk). We used kilocalories as the unit of energy expenditure because this unit is widely understood by physicians and patients. However, body weight is used in the computation of energy expenditure in kilocalories per week (ie, for the same activity, a heavier person expends more kilocalories than a lighter person). Thus, we repeated analyses using energy expenditure estimated in MET-hours, a unit that is independent of body weight (ie, for the same activity, heavier and lighter persons expend the same MET-hours).

At study entry, participants also reported information on smoking, diet, menopausal status, hormone use, weight, height, blood pressure, history of hypertension (blood pressure $\geq 140/90$ mm Hg or use of antihypertensive medication) and diabetes, and family history.

Laboratory Measurements

EDTA blood samples were obtained at the time of enrollment in the WHS and stored in vapor-phase liquid nitrogen (-170°C). Hemoglobin A1c was assessed with an immunoturbidimetric assay (Roche Diagnostics, Indianapolis, Ind). Total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol was assayed with reagents from Genzyme Corp (Cambridge, Mass) and Roche Diagnostics. Lipoprotein(a) was measured with an immunoturbidimetric assay (Roche Diagnostics) with reagents and calibrators from Denka Seiken (Tokyo, Japan). Apolipoproteins A1 and B-100 were measured with immunoturbidimetric assays (DiaSorin, Stillwater, Minn). Creatinine was measured by a rate-blanked method that is based on the Jaffé reaction using Roche Diagnostics reagents. An enzymatic assay was used to measure homocysteine (Catch Inc, Seattle, Wash). High-sensitivity C-reactive protein (CRP) was measured with a high-sensitivity immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics) using reagents and calibrators from Denka Seiken. Fibrinogen was measured with an immunoturbidimetric assay (Kamiya Biomedical, Seattle, Wash); soluble intracellular adhesion molecule-1 (ICAM-1) was measured with an ELISA assay (R&D Systems, Minneapolis, Minn).

Ascertainment of CVD Events

The primary end point of interest was a composite end point of incident CVD (nonfatal myocardial infarction [MI], nonfatal ische-

mic stroke, percutaneous coronary intervention, coronary artery bypass grafting, or cardiovascular death). Other end points were incident coronary heart disease (CHD; nonfatal MI, percutaneous coronary intervention, coronary artery bypass grafting, or coronary death) and the individual CVD end points. Women reported the end points of interest on follow-up questionnaires every 6 or 12 months, and confirmed events were included in analyses as previously described.²¹

Statistical Analysis

Statistical analyses were performed with STATA version 8.2 (STATA Corp, College Station, Tex). We categorized participants into approximate quartiles of energy expenditure (<200 , 200 to 599, 600 to 1499, and ≥ 1500 kcal/wk); the highest activity category corresponds to ≈ 5 hours of moderate-intensity activity per week.²³ Cox proportional-hazard regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) according to these activity groups. Tests for linear trend were performed using the median value for each activity group. All probability values were 2 tailed.

To examine the extent to which various CVD risk factors contributed to the risk reduction in events associated with activity, we initially considered each risk factor separately in a model that adjusted for age and randomized treatment assignment. We considered the magnitude of change in the HRs for the most active women compared with the least with and without adjustment for each risk factor. A larger change in the HR toward the null implies a larger mediating effect of that risk factor on the activity-related reduction in CVD.

Then, on an a priori basis, we grouped together a set of variables that are generally considered to be potential confounders rather than mediators (smoking; dietary intake of alcohol, fruits, and vegetables; consumption of saturated fat and fiber; menopause; hormone use; and parental history of MI before 60 years of age). We included this set of variables, together with age and randomized treatment assignment, in a single model, referring to this model as the basic model.

Also on an a priori basis, we grouped other CVD risk factors generally considered to be potential mediators into sets of risk factors on the basis of their pathophysiological effects. Blood pressure and the presence or absence of hypertension were combined as 1 set. Hemoglobin A1c and the presence or absence of diabetes were combined as another set. To consider the combined effect of traditional lipids, we combined total, LDL, and HDL cholesterol into 1 set, with a similar analysis for novel lipids [lipoprotein(a), apolipoprotein A1 and B-100]. High-sensitivity CRP, fibrinogen, and soluble ICAM-1 were considered as a group related to inflammatory and hemostatic pathways. Finally, body mass index and homocysteine were examined separately.

To examine the extent to which CVD risk factors potentially mediated the effect of activity on incident CVD, we next added these risk factors, 1 set at a time, to the basic model and examined the magnitude of change in the HRs for the most active women compared with the least without (basic model) and with adjustment for each set of risk factors (adjusted model). Finally, we performed a fully adjusted analysis that included all the CVD risk factors simultaneously. The proportion of CVD risk reduction explained by each set of CVD risk factors was computed as follows^{24,25}:

$$(\text{HR}_{\text{basic model}} - \text{HR}_{\text{adjusted model}}) / (\text{HR}_{\text{basic model}} - 1) \times 100\%.$$

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results

Table 1 shows the baseline characteristics of participants according to their activity levels. Active women had a healthier lifestyle, weighed less, and had better risk factor profiles than inactive women. There were modest but statistically significant differences in all biomarkers except li-

Table 1. Baseline Characteristics of Participants According to Physical Activity

	Physical Activity, kcal/wk			
	<200 (n=6789)	200–599 (n=6732)	600–1499 (n=7681)	≥1500 (n=5853)
Age, mean (SD), y	54.7 (7.1)	54.4 (7.0)	54.8 (7.1)	54.7 (7.1)
Current smoking, %	17.1	11.9	9.1	7.9
Alcohol consumption, %				
Rarely	52.3	44.5	40.6	38.2
1–3 drinks/mo	12.6	13.6	13.5	13.5
1–6 drinks/wk	26.2	31.2	35.0	37.0
≥1 drink/d	8.9	10.7	10.8	11.2
Fruit and vegetable intake, mean (SD), servings/d	5.2 (3.3)	5.9 (3.2)	6.4 (3.6)	7.3 (4.0)
Saturated fat intake, mean (SD), g/d	20.5 (8.5)	20.2 (7.9)	19.3 (7.7)	18.8 (7.9)
Fiber intake, mean (SD), g/d	16.7 (7.4)	18.7 (7.6)	19.8 (8.0)	21.6 (9.2)
Hypertension, %	28.6	24.7	23.0	23.8
Diabetes, %	3.5	2.5	2.5	2.4
Postmenopausal status, %	54.9	53.1	54.2	54.8
Postmenopausal hormone use, %	41.4	43.9	44.3	44.6
Body mass index, mean (SD), kg/m ²	26.9 (5.6)	25.9 (4.9)	25.3 (4.5)	25.6 (4.7)
Parental history of MI <60 y, %	13.6	12.4	12.6	12.8
Biomarkers, median (IQR)				
Hemoglobin A1c, mg/dL	5.03 (4.86–5.23)	5.00 (4.84–5.19)	4.99 (4.83–5.18)	4.99 (4.83–5.17)
Total cholesterol, mg/dL	210 (186–237)	209 (184–236)	207 (183–234)	207 (182–234)
LDL cholesterol, mg/dL	124 (103–147)	122 (102–145)	120 (99–143)	119 (98–142)
HDL cholesterol, mg/dL	49.5 (41.3–60.2)	51.6 (43.4–61.9)	53.1 (44.1–63.1)	53.5 (44.1–64.3)
Lipoprotein(a), mg/dL	10.4 (4.3–31.0)	10.9 (4.4–34.0)	10.6 (4.6–32.6)	10.5 (4.4–33.1)
Apolipoprotein A1, mg/dL	146 (130–164)	149 (133–167)	150 (134–169)	151 (134–170)
Apolipoprotein B-100, mg/dL	105 (87–124)	103 (84–122)	99 (83–119)	98 (82–119)
Creatinine, mg/dL	0.70 (0.62–0.79)	0.71 (0.63–0.80)	0.71 (0.63–0.80)	0.72 (0.64–0.81)
Homocysteine, μmol/L	10.8 (8.9–13.3)	10.4 (8.6–12.8)	10.3 (8.7–12.6)	10.4 (8.6–12.8)
High-sensitivity CRP, mg/L	2.5 (1.0–5.1)	2.0 (0.8–4.4)	1.8 (0.7–4.1)	1.8 (0.7–3.8)
Fibrinogen, mg/dL	362 (315–416)	351 (308–402)	347 (305–398)	344 (303–395)
Soluble ICAM-1, ng/mL	356 (309–414)	342 (301–394)	338 (297–386)	337 (298–384)

IQR indicates interquartile range. Probability values across physical activity categories were all <0.05 except for postmenopausal status ($P=0.05$), parental history ($P=0.20$), and lipoprotein(a) ($P=0.25$).

poprotein(a), with higher activity associated with better profiles (P for linear trend <0.001).

During a mean follow-up of 10.9 ± 1.6 years, a total of 979 first CVD events occurred, including 640 CHD events (253 MIs, 398 percutaneous coronary interventions, and 219 coronary artery bypass grafts) and 266 ischemic strokes. The risk of incident CVD decreased linearly with higher levels of activity (P for linear trend <0.001; Table 2). Using the reference group of <200 kcal/wk of activity and after adjusting for age and randomized-treatment assignment, we found relative risk reductions associated with 200 to 599, 600 to 1499, and ≥ 1500 kcal/wk of 27%, 32%, and 41%, respectively. In separate Cox regression models that considered each risk factor variable, 1 at a time, and adjusted for age and treatment assignment (Table 2), there was some attenuation noted in the HRs comparing the most active women with the least active before and after adjustment for all variables, except for creatinine, lipoprotein(a), and postmenopausal status/hormone use. However, when all risk factors

were combined in 1 model, the HR comparing the most active women with the least active was substantially attenuated (after adjustment for all risk factors: HR, 0.90; 95% CI, 0.73 to 1.11; after adjusting for only age and treatment assignment: HR, 0.59; 95% CI, 0.49 to 0.71), and the linear trend across activity levels was no longer significant (P for linear trend=0.37).

Next, to determine the extent to which the reduced risk of CVD associated with activity was influenced by potential mediators representing various physiological pathways, each set of mediators was added, 1 set at a time, to the basic model (Table 3, top). For CVD, the addition of blood pressure/hypertension resulted in an attenuation of the inverse relation, which became nonsignificant (P for trend=0.09), with similar results for the inflammatory/hemostatic biomarkers (P for trend=0.10). The addition of body mass index, hemoglobin A1c/diabetes, traditional lipids, and novel lipids, 1 set at a time, resulted in smaller attenuations in the inverse relation between activity and CVD (all P for trend ≤ 0.05). Adding all

Table 2. Association of Physical Activity With CVD Events After Adjustment for CVD Risk Factors

	Physical Activity, kcal/wk				<i>P</i> for Trend
	<200	200–599	600–1499	≥1500	
Age- and treatment-adjusted model	1.00	0.73 (0.61–0.86)	0.68 (0.57–0.80)	0.59 (0.49–0.71)	<0.001
Age- and treatment-adjusted model plus each of the following added 1 at a time					
Smoking	1.00	0.76 (0.64–0.90)	0.72 (0.61–0.85)	0.62 (0.52–0.75)	<0.001
Alcohol consumption	1.00	0.73 (0.62–0.87)	0.69 (0.58–0.81)	0.60 (0.50–0.73)	<0.001
Fruit, vegetable, saturated fat, fiber intake	1.00	0.76 (0.64–0.90)	0.71 (0.60–0.84)	0.66 (0.54–0.80)	<0.001
Postmenopausal status, hormone use	1.00	0.74 (0.62–0.87)	0.68 (0.58–0.81)	0.59 (0.49–0.72)	<0.001
Parental history of MI <60 y	1.00	0.77 (0.64–0.92)	0.71 (0.60–0.85)	0.62 (0.51–0.76)	<0.001
Hypertension	1.00	0.75 (0.64–0.89)	0.71 (0.60–0.84)	0.62 (0.51–0.74)	<0.001
Blood pressure	1.00	0.77 (0.65–0.92)	0.75 (0.63–0.88)	0.66 (0.54–0.79)	<0.001
Diabetes	1.00	0.75 (0.64–0.89)	0.69 (0.59–0.82)	0.61 (0.51–0.74)	<0.001
Hemoglobin A1c	1.00	0.76 (0.64–0.90)	0.72 (0.61–0.85)	0.63 (0.52–0.76)	<0.001
Body mass index	1.00	0.77 (0.65–0.91)	0.74 (0.63–0.87)	0.63 (0.52–0.76)	<0.001
Total cholesterol	1.00	0.73 (0.62–0.87)	0.69 (0.58–0.81)	0.60 (0.50–0.72)	<0.001
LDL cholesterol	1.00	0.73 (0.62–0.87)	0.69 (0.58–0.81)	0.60 (0.50–0.72)	<0.001
HDL cholesterol	1.00	0.76 (0.64–0.90)	0.72 (0.61–0.85)	0.64 (0.53–0.77)	<0.001
Lipoprotein(a)	1.00	0.72 (0.61–0.85)	0.67 (0.57–0.79)	0.58 (0.48–0.70)	<0.001
Apolipoprotein A1	1.00	0.75 (0.63–0.89)	0.70 (0.60–0.83)	0.62 (0.51–0.74)	<0.001
Apolipoprotein B-100	1.00	0.75 (0.63–0.89)	0.72 (0.61–0.84)	0.62 (0.52–0.75)	<0.001
Creatinine	1.00	0.73 (0.61–0.86)	0.67 (0.57–0.80)	0.59 (0.49–0.71)	<0.001
Homocysteine	1.00	0.73 (0.62–0.87)	0.69 (0.58–0.81)	0.60 (0.49–0.72)	<0.001
High-sensitivity CRP	1.00	0.77 (0.65–0.91)	0.73 (0.62–0.86)	0.64 (0.53–0.77)	<0.001
Fibrinogen	1.00	0.76 (0.64–0.89)	0.72 (0.61–0.85)	0.63 (0.52–0.76)	<0.001
Soluble ICAM-1	1.00	0.77 (0.65–0.91)	0.73 (0.62–0.86)	0.64 (0.53–0.77)	<0.001
All the above in 1 model	1.00	0.95 (0.79–1.15)	0.95 (0.79–1.14)	0.90 (0.73–1.11)	0.37

Values are HRs (95% CIs).

sets of risk factors simultaneously to the basic model resulted in further attenuation of the HRs, and no significant associations were observed (*P* for trend=0.36).

For CHD, a broadly similar pattern was observed (Table 3, bottom). Unlike CVD, there remained a borderline-significant inverse association with CHD after adjustment for all sets of risk factors (*P* for trend=0.05).

The associations of activity with nonfatal MI, percutaneous coronary intervention, and coronary artery bypass grafting, when examined as separate end points, are shown in Table 4. When the sets of potential mediators were added to the basic model, the effect of physical activity was attenuated in a manner similar to that seen with CHD. The association of activity with ischemic stroke was nonlinear (corresponding age- and treatment-adjusted HRs and 95% CIs: 1.00, 0.68 [95% CI, 0.49 to 0.95], 0.69 [95% CI, 0.50 to 0.95], and 0.72 [95% CI, 0.51 to 1.01], respectively; *P* for trend=0.16).

Finally, we computed the proportion of the physical activity-related reduction in CVD or CHD events explained by each set of potential mediators (Figure). A large proportion (59.0%) of the inverse relation between physical activity and CVD risk was explained by the potential mediators that we investigated. When examined as sets of risk factors,

inflammatory/hemostatic biomarkers were the largest contributors to lower risk (32.6%), followed by blood pressure (27.1%). Novel lipids [lipoprotein(a), apolipoprotein A1 and B-100] contributed less to CVD risk reduction than traditional lipids (total, LDL, and HDL cholesterol): 15.5% and 19.1%, respectively. Smaller contributions were attributed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine had negligible effects (<1%). A similar but smaller pattern was observed for CHD (35.5% of the CHD event risk reduction explained by risk factors compared with 59.0% for CVD).

We repeated our analyses (Figure, B), calculating activity expenditure in MET-hours per week instead of kilocalories per week. Almost identical results were obtained except for body mass index, the contribution of which increased from 10.1% to 21.9%, and hemoglobin A1c/diabetes, which increased from 8.9% to 12.2%.

Discussion

Although physical activity has clearly been shown to reduce the risk of developing CVD, the biological mechanisms underlying this association are unclear, as is the extent to which various pathways might underlie the inverse association. This study indicates that the association between higher levels of activity and lower CVD rates can be explained in

Table 3. Association of Physical Activity With CVD and CHD Events After Adjustment for Sets of Potential Mediators

	Physical Activity, kcal/wk				<i>P</i> for Trend
	<200	200–599	600–1499	≥1500	
CVD					
Age- and treatment-adjusted model	1.00	0.73 (0.61–0.86)	0.68 (0.57–0.80)	0.59 (0.49–0.71)	<0.001
Basic model*	1.00	0.86 (0.72–1.04)	0.82 (0.68–0.98)	0.75 (0.61–0.93)	0.01
Basic model plus each set of risk factors below, added 1 group at a time†					
Blood pressure/hypertension	1.00	0.91 (0.75–1.09)	0.89 (0.74–1.08)	0.82 (0.66–1.01)	0.09
Body mass index	1.00	0.90 (0.75–1.08)	0.88 (0.73–1.05)	0.78 (0.63–0.96)	0.02
Hemoglobin A1c/diabetes	1.00	0.89 (0.74–1.07)	0.83 (0.69–1.00)	0.77 (0.62–0.95)	0.02
Traditional lipids: total, LDL, HDL cholesterol	1.00	0.90 (0.74–1.08)	0.87 (0.72–1.05)	0.80 (0.65–0.99)	0.05
Novel lipids: Lp(a), Apo A1, Apo B-100	1.00	0.88 (0.73–1.06)	0.85 (0.71–1.02)	0.79 (0.64–0.97)	0.04
Homocysteine	1.00	0.87 (0.72–1.04)	0.82 (0.68–0.99)	0.75 (0.61–0.93)	0.01
Inflammatory/hemostatic hsCRP, fibrinogen, sICAM-1	1.00	0.93 (0.77–1.12)	0.91 (0.75–1.09)	0.83 (0.67–1.03)	0.10
All of the above‡	1.00	0.95 (0.79–1.15)	0.95 (0.79–1.14)	0.90 (0.73–1.11)	0.36
CHD					
Age- and treatment-adjusted model	1.00	0.71 (0.58–0.87)	0.64 (0.52–0.78)	0.48 (0.38–0.62)	<0.001
Basic model	1.00	0.84 (0.67–1.06)	0.76 (0.61–0.96)	0.62 (0.48–0.82)	0.001
Basic model plus each set of risk factors below, added 1 group at a time					
Blood pressure/hypertension	1.00	0.88 (0.70–1.11)	0.84 (0.67–1.05)	0.68 (0.52–0.89)	0.006
Body mass index	1.00	0.89 (0.71–1.11)	0.83 (0.66–1.04)	0.65 (0.50–0.85)	0.002
Hemoglobin A1c/diabetes	1.00	0.87 (0.69–1.08)	0.78 (0.62–0.98)	0.64 (0.49–0.84)	0.001
Traditional lipids: total, LDL, HDL cholesterol	1.00	0.88 (0.70–1.10)	0.83 (0.66–1.04)	0.67 (0.52–0.88)	0.005
Novel lipids: Lp(a), Apo A1, Apo B-100	1.00	0.86 (0.69–1.08)	0.81 (0.64–1.01)	0.67 (0.51–0.87)	0.004
Homocysteine	1.00	0.85 (0.68–1.06)	0.77 (0.61–0.96)	0.63 (0.48–0.82)	0.001
Inflammatory/hemostatic hsCRP, fibrinogen, sICAM-1	1.00	0.91 (0.73–1.14)	0.86 (0.68–1.08)	0.70 (0.54–0.92)	0.01
All of the above	1.00	0.93 (0.74–1.17)	0.89 (0.71–1.13)	0.76 (0.58–0.99)	0.05

Lp indicates lipoprotein; Apo, lipoprotein; and sICAM-1, soluble ICAM-1. Values are HRs (95% CIs).

*Basic models included age; randomized treatment assignment; smoking; consumption of alcohol, fruits and vegetables; intake of saturated fat and fiber; menopausal status; postmenopausal hormone use; and parental history of MI.

†Models were adjusted for the variables in the basic model plus each of the sets of risk factors added 1 group at a time to separate models.

‡Model included variables in the basic model, plus all sets of risk factors included simultaneously in 1 model.

large part by known risk factors, both traditional and novel. The risk factors investigated in this study explained 59.0% of the activity-related reduction in CVD, with inflammatory/hemostatic biomarkers making the largest contribution to lowered risk, followed by blood pressure, lipids, and body mass index. A smaller contribution was attributed to measures of glucose abnormalities, with minimal contribution observed from measures of renal function or homocysteine.

The beneficial effect of physical activity was stronger for CHD compared with CVD in this study, but the relative contributions of potential mediators were proportional and qualitatively similar. Previous studies have noted nonlinear associations or weak or positive associations between activity and stroke,^{26,27} as did we.

Prior studies have demonstrated favorable effects of physical activity on traditional risk factors.^{9,28–30} Although some individuals may experience large changes in risk factors with exercise,³¹ most individuals experience modest short-term changes, on the order of 2% to 5%.^{8–12} The effect of exercise on inflammatory factors has been recognized more recently.^{13,17,32} Acute bouts of exercise result in

a transient, mostly proinflammatory, several-fold increase in acute-phase reactants and cytokines,³³ proportional to the amount of exercise and muscle injury.³²

In contrast, regular activity also has been associated with a chronic antiinflammatory effect, with moderate (≈20% to 30%) reductions in CRP and soluble ICAM and vascular adhesion molecules.^{34,35} We previously demonstrated that in this population of women, the highest versus lowest level of activity was associated with ≈43% lower high-sensitivity CRP level, which was mildly attenuated to 37% after adjustment for the other risk factors, including body mass index.¹⁸ The mechanisms underlying the chronic antiinflammatory and hemostatic effects of exercise are not well defined and are only partially related to body weight.^{18,36} Other explanations include possible effects on proatherogenic adipokines, insulin-sensitizing pathways, or the hemostatic and antioxidant functions of the coronary endothelium.^{32,37} Regular exercise attenuates the age-associated increase in oxidative stress and nuclear factor-κB activation in animals³⁸ and reduces toll-like receptor 4 signaling, which may explain the chronic antiinflammatory effect of exercise.^{39–40}

Table 4. Association of Physical Activity With MI and Coronary Revascularization Procedures After Adjustment for Sets of Potential Mediators

	Physical Activity, kcal/wk				
	<200	200–599	600–1499	≥1500	<i>P</i> for Trend
MI					
Age- and treatment-adjusted model	1.00	0.63 (0.45–0.87)	0.62 (0.45–0.85)	0.44 (0.30–0.65)	<0.001
Basic model	1.00	0.77 (0.54–1.11)	0.79 (0.56–1.13)	0.53 (0.34–0.83)	0.009
Basic model plus each set of risk factors below, added one group at a time					
Blood pressure/hypertension	1.00	0.84 (0.58–1.20)	0.89 (0.62–1.28)	0.58 (0.37–0.91)	0.03
Body mass index	1.00	0.81 (0.56–1.16)	0.85 (0.60–1.22)	0.55 (0.35–0.86)	0.01
Hemoglobin A1c/diabetes	1.00	0.81 (0.56–1.16)	0.82 (0.57–1.17)	0.55 (0.35–0.86)	0.01
Traditional lipids: total, LDL, HDL cholesterol	1.00	0.81 (0.56–1.16)	0.86 (0.60–1.22)	0.57 (0.36–0.89)	0.02
Novel lipids: Lp(a), Apo A1, Apo B-100	1.00	0.79 (0.55–1.13)	0.83 (0.58–1.18)	0.56 (0.36–0.87)	0.02
Homocysteine	1.00	0.78 (0.54–1.12)	0.80 (0.56–1.14)	0.53 (0.34–0.83)	0.01
Inflammatory/hemostatic hsCRP, fibrinogen, sICAM-1	1.00	0.83 (0.57–1.19)	0.87 (0.61–1.25)	0.58 (0.37–0.91)	0.03
All of the above	1.00	0.88 (0.61–1.28)	0.95 (0.66–1.36)	0.64 (0.41–1.00)	0.07
Percutaneous coronary intervention					
Age- and treatment-adjusted model	1.00	0.74 (0.57–0.95)	0.55 (0.42–0.71)	0.44 (0.33–0.60)	<0.001
Basic model	1.00	0.90 (0.68–1.18)	0.67 (0.50–0.90)	0.58 (0.41–0.83)	0.001
Basic model plus each set of risk factors below, added one group at a time					
Blood pressure/hypertension	1.00	0.94 (0.71–1.24)	0.72 (0.54–0.97)	0.63 (0.44–0.89)	0.004
Body mass index	1.00	0.95 (0.72–1.25)	0.73 (0.54–0.99)	0.61 (0.43–0.87)	0.002
Hemoglobin A1c/diabetes	1.00	0.92 (0.70–1.21)	0.69 (0.51–0.93)	0.60 (0.42–0.86)	0.002
Traditional lipids: total, LDL, HDL cholesterol	1.00	0.95 (0.72–1.25)	0.74 (0.55–1.00)	0.64 (0.45–0.91)	0.006
Novel lipids: Lp(a), Apo A1, Apo B-100	1.00	0.93 (0.70–1.22)	0.71 (0.53–0.96)	0.63 (0.45–0.90)	0.005
Homocysteine	1.00	0.90 (0.68–1.18)	0.67 (0.50–0.90)	0.58 (0.41–0.83)	0.001
Inflammatory/hemostatic hsCRP, fibrinogen, sICAM-1	1.00	0.97 (0.74–1.28)	0.76 (0.56–1.02)	0.66 (0.46–0.94)	0.009
All of the above	1.00	1.01 (0.76–1.33)	0.79 (0.59–1.07)	0.71 (0.50–1.01)	0.03
Coronary artery bypass graft surgery					
Age- and treatment-adjusted model	1.00	0.64 (0.44–0.92)	0.74 (0.53–1.04)	0.64 (0.43–0.94)	0.09
Basic model	1.00	0.70 (0.46–1.05)	0.82 (0.56–1.21)	0.80 (0.52–1.22)	0.58
Basic model plus each set of risk factors below, added 1 group at a time					
Blood pressure/hypertension	1.00	0.72 (0.48–1.10)	0.94 (0.64–1.39)	0.89 (0.58–1.38)	1.00
Body mass index	1.00	0.74 (0.49–1.11)	0.90 (0.61–1.32)	0.83 (0.54–1.28)	0.69
Hemoglobin A1c/diabetes	1.00	0.73 (0.48–1.10)	0.85 (0.58–1.25)	0.85 (0.55–1.31)	0.74
Traditional lipids: total, LDL, HDL cholesterol	1.00	0.73 (0.49–1.10)	0.90 (0.61–1.32)	0.87 (0.56–1.33)	0.84
Novel lipids: Lp(a), Apo A1, Apo B-100	1.00	0.71 (0.47–1.08)	0.88 (0.60–1.29)	0.84 (0.55–1.30)	0.77
Homocysteine	1.00	0.70 (0.46–1.05)	0.83 (0.56–1.21)	0.80 (0.52–1.23)	0.58
Inflammatory/hemostatic hsCRP, fibrinogen, sICAM-1	1.00	0.76 (0.51–1.15)	0.94 (0.64–1.38)	0.92 (0.60–1.41)	1.00
All of the above	1.00	0.78 (0.51–1.19)	1.04 (0.70–1.53)	1.04 (0.67–1.61)	0.54

Abbreviations as in Table 3. Values are HRs (95% CIs).


Several limitations of the present study warrant consideration. Physical activity and several of the risk factors were assessed by self-report. It is possible that more precise assessment of these factors may have resulted in a different contribution of these variables to the reduction in CVD risk. The study design was observational but prospectively collected. We did not have information on other variables that are favorably influenced by physical activity, such as those related to heart rate or autonomic balance,⁴¹ baseline waist circumference or insulin sensitivity,⁴² and nitric oxide-dependent endothelial activity,⁴³

so we could not evaluate their contributions to the inverse relation between physical activity and CVD risk.

This study also has several strengths, including the large number of women investigated, detailed information on physical activity, a wide range of traditional and novel CVD risk factors, and the long duration of follow-up for the various cardiovascular end points.

In summary, to the best of our knowledge, this is the first study to attempt to quantify the relative importance of potential underlying mechanisms through which higher levels of physical activity are associated with lower risk of

A. Kcal/week



B. MET hr/week




Figure. Percentage reduction in CVD events associated with physical activity that is explained by risk factors. The proportion of the risk reduction for ≥ 1500 kcal/wk of physical activity (versus the reference group of < 200 kcal/wk; A) and for > 20.5 MET h/wk (versus the reference group of < 2.8 MET h/wk; B) that is explained by each set of potential risk factors calculated as follows: $(HR_{\text{basic model}} - HR_{\text{adjusted model}}) / (HR_{\text{basic model}} - 1) \times 100\%$.²⁴ These proportions were calculated from HRs expressed up to 5 decimal points for greater accuracy and thus may differ slightly from the data shown in Table 3. HbA1c indicates hemoglobin A1c.

CVD events. In this study, we have identified potential underlying mechanisms through which even moderate levels of physical activity (at least 600 kcal/wk, or the equivalent of just over 2 h/wk of brisk walking, consistent with current guideline recommendations)⁴⁴ are associated with lower risk of clinically important CVD events.

Modest changes in known CVD risk factors, particularly those relating to inflammation/hemostasis and blood pressure, account for a substantial portion of the benefit of physical activity on CVD risk and thus may have important downstream consequences for the primary prevention of CVD.

Sources of Funding

The research for this article was supported by grants from the Donald W. Reynolds Foundation, Leducq Foundation, and Doris Duke Charitable Foundation. The WHS is supported by grants HL-43851 and CA-47988 from the National Heart, Lung, and Blood Institute, grants from the National Cancer Institute, and philanthropic support from Elisabeth and Alan Doft and their family. Dr Mora is supported by the Sandra Daugherty Foundation and grant 0670007N from the American Heart Association. The funding agencies played no role in the design, conduct, data management, analysis, or manuscript preparation related to this article.

Disclosures

Dr Ridker is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease. Dr Lee has served as a consultant for Virgin Life Care and sits on its Scientific Advisory Board. The other authors report no conflicts.

References

- Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA*. 1996;276:205–210.
- Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. *N Engl J Med*. 2002;347:716–725.
- Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. *N Engl J Med*. 1986;314:605–613.
- Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. *JAMA*. 1989;262:2395–2401.
- Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study. *Arch Intern Med*. 1998;158:1499–1505.
- Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. *Am J Epidemiol*. 2002;156:832–841.
- Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. *N Engl J Med*. 2004;351:2694–2703.
- Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. *Med Sci Sports Exerc*. 2001;33:S502–S515.
- Kraus WE, Houmard JA, Duscha BD, Knetzer KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med*. 2002;347:1483–1492.
- Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. *Med Sci Sports Exerc*. 2001;33:S484–S492.
- Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med*. 2002;136:493–503.
- Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L. The acute versus the chronic response to exercise. *Med Sci Sports Exerc*. 2001;33:S438–S445.
- Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. *Circulation*. 2002;105:1785–1790.
- Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. *Arch Intern Med*. 2002;162:1286–1292.
- Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute–National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. *Circulation*. 2002;105:2923–2928.
- Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. *Int J Obes Relat Metab Disord*. 2002;26:805–813.
- Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. *Arterioscler Thromb Vasc Biol*. 2002;22:1869–1876.
- Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. *JAMA*. 2006;295:1412–1419.
- Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. *JAMA*. 2005;294:47–55.
- Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. *JAMA*. 2005;294:56–65.
- Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352:1293–1304.
- Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA, Rosner B, Kriska A, Willett WC. Reproducibility and validity of a self-administered physical activity questionnaire. *Int J Epidemiol*. 1994;23:991–999.
- Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE. Physical activity and coronary heart disease in women: is "no pain, no gain" passé? *JAMA*. 2001;285:1447–1454.
- Rothman KJ, Greenland S. Measures of effect and association. In: *Modern Epidemiology*. Philadelphia, Pa: Lippincott Williams & Wilkins; 1998:47–64.
- Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. *JAMA*. 2006;295:784–792.
- Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. *Stroke*. 2003;34:2475–2481.
- Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, Kromhout D. Physical activity and stroke: a meta-analysis of observational data. *Int J Epidemiol*. 2004;33:787–798.
- Ivy JL. Role of insulin during exercise-induced glycogenesis in muscle: effect on cyclic AMP. *Am J Physiol*. 1977;233:E509–E513.
- Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. *JAMA*. 1999;281:327–334.
- Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. *JAMA*. 2003;290:1323–1330.
- Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation*. 2003;107:3109–3116.
- Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. *J Am Coll Cardiol*. 2005;45:1563–1569.
- Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. *J Physiol*. 1998;513:889–894.
- Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? *Eur J Vasc Endovasc Surg*. 1997;14:344–350.
- Adamopoulos S, Parissis J, Kroupis C, Georgiadis M, Karatzas D, Karavoliis G, Koniavitou K, Coats AJ, Kremastinos DT. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. *Eur Heart J*. 2001;22:791–797.
- Hamer M. The relative influences of fitness and fatness on inflammatory factors. *Prev Med*. 2006;44:3–11.
- Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. *N Engl J Med*. 2000;342:454–460.
- Radak Z, Chung HY, Naito H, Takahashi R, Jung KJ, Kim HJ, Goto S. Age-associated increase in oxidative stress and nuclear factor kappaB activation are attenuated in rat liver by regular exercise. *FASEB J*. 2004;18:749–750.

39. McFarlin BK, Flynn MG, Phillips MD, Stewart LK, Timmerman KL. Chronic resistance exercise training improves natural killer cell activity in older women. *J Gerontol A Biol Sci Med Sci*. 2005;60:1315–1318.
40. Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. *Brain Behav Immun*. 2005;19:389–397.
41. Lauer MS, Froelicher V. Abnormal heart-rate recovery after exercise. *Lancet*. 2002;360:1176–1177.
42. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? *J Clin Endocrinol Metab*. 2001;86:3257–3265.
43. Zhao G, Zhang X, Xu X, Ochoa M, Hintze TH. Short-term exercise training enhances reflex cholinergic nitric oxide-dependent coronary vasodilation in conscious dogs. *Circ Res*. 1997;80:868–876.
44. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;39:1423–1434.

CLINICAL PERSPECTIVE

Higher levels of physical activity are associated with fewer cardiovascular disease (CVD) events. Although the precise mechanisms underlying this inverse association are unclear, differences in several cardiovascular risk factors may mediate this effect. Changes in individual risk factors with physical activity tend to be modest, on the order of 5% for blood lipids, 3 to 5 mm Hg for blood pressure, and 1% for hemoglobin A1c, in contrast to the large reductions (30% to 50%) in CVD events seen with physical activity. We examined the extent to which traditional and novel risk factors explain the cardioprotective benefit of activity. Using prospectively collected data from the Women's Health Study with 27 055 initially healthy women followed up for 11 years, we found that even moderate levels of physical activity (at least 600 kcal/wk or the equivalent of just over 2 h/wk of brisk walking, consistent with current guideline recommendations) are associated with substantially lower risk of clinically important CVD events (30% to 40% relative risk reduction). The risk factors that were investigated in this study explained, in sum, 59% of the activity-related reduction in CVD. Inflammatory/hemostatic biomarkers (high-sensitivity C-reactive protein, fibrinogen, and soluble intracellular adhesion molecule-1) provided the largest contribution to lowered risk (33%), followed by blood pressure (27%), lipids (19%), body mass index (10%), and glucose abnormalities (9%), with minimal contribution observed from measures of renal function or homocysteine (<1%). Modest changes in known CVD risk factors, particularly inflammation/hemostasis and blood pressure, may account for a substantial portion of the benefit of physical activity on CVD risk reduction.